# A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH

> **NCT03985423** · PHASE2,PHASE3 · TERMINATED · sponsor: **Swedish Orphan Biovitrum** · enrollment: 7 (actual)

## Conditions studied

- Hemophagocytic Lymphohistiocytoses

## Interventions

- **DRUG:** Emapalumab-Lzsg

## Key facts

- **NCT ID:** NCT03985423
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-02
- **Primary completion:** 2021-06-29
- **Final completion:** 2021-06-29
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2023-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03985423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03985423, "A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03985423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*